As experts raise awareness of the evidence supporting shorter antibiotic therapy for some conditions and the benefits of oral vs. IV-only therapy for others, we wanted to know: What is another ID dogma that should be reevaluated? We asked Joshua Barocas, associate professor of medicine at the University of Colorado School of Medicine and chair of the Infectious Diseases Society of America’s Public Health Committee.